. "2"^^ . "\u0158\u00EDhov\u00E1 (Lenderov\u00E1), Zuzana" . . "Libiger, Jan" . . . "Multisyst\u00E9mov\u00E1 atrofie (MSA) je sporadick\u00E1 neurodegenerativn\u00ED choroba neur\u010Dit\u00E9 etiologie a patogeneze. Klinicky se jedn\u00E1 o kombinace extrapyramid\u00E1ln\u00EDch, cerebel\u00E1rn\u00EDch, pyramid\u00E1ln\u00EDch a autonomn\u00EDch dysfunkc\u00ED. Diagn\u00F3za stanovuje podle krit\u00E9ri\u00ED mo\u017Enou, pravd\u011Bpodobnou a definitivn\u00ED MSA. N\u00E1\u0161 pacient je \u010Dty\u0159iat\u0159icetilet\u00FD mu\u017E, kter\u00FD trp\u00ED atypickou neurologickou symptomatologi\u00ED a kognitivn\u00ED poruchou neur\u010Dit\u00E9 etiologie.Tento p\u0159\u00EDpad ilustruje relevanci detailn\u00EDho neuropsychologick\u00E9ho hodnocen\u00ED a u\u017Eite\u010Dnost kvantitativn\u00EDho rozboru D2 receptoru pomoc\u00ED 123I-IBMZ SPECT u pacient\u016F s norm\u00E1ln\u00ED MRI a s podez\u0159en\u00EDm na MSA. P\u0159\u00EDtomnost demence se nepova\u017Euje za znak MSA. Kognitivn\u00ED porucha je v tomto p\u0159\u00EDpad\u011B jednou z inici\u00E1ln\u00EDch syndrom\u016F a \u0159ad\u00ED se k rozs\u00E1hl\u00E9 klinickopatologick\u00E9 komplexit\u011B MSA. Vzhledem k tomu, \u017Ee \u017E\u00E1dn\u00E1 l\u00E9\u010Debn\u00E1 terapie nen\u00ED zn\u00E1ma, l\u00E9\u010Dba je p\u0159edev\u0161\u00EDm podp\u016Frn\u00E1."@cs . "1211-7579" . . "[14A8131EDBA1]" . "11150" . "7"^^ . "Multiple system atrophy (MSA) is a sporadic neurodegenerative disease of undetermined etiology and pathogenesis. Clinically, there are combinations of extrapyramidal, cerebellar, pyramidal and autonomic dysfunctions. Diagnosis is sorted according to criteria into possible, probable and definite MSA. Our patient is a 43-year-old man who suffred from atypical neurological symptomatology and cognitive impairment of uncertain etiology. There was no family history of neurodegenerative disease. This case ilustrates the relevance of detailed neuropsychological assessment and that D2 receptor assay with 123I-IBMZ SPECT may be helpful in patients with normal MRI and questionable MSA. The presence of dementia is considered not to be a feature of MSA. Cognitive impairment was one of initial syndrome in this case and it adds to the great clinicopathological complexity of MSA. Treatment is mainly supportive, as no curative therapy is known."@en . "7" . "Multiple System Atrophy with Dementia"@en . . "5"^^ . . . . "Vali\u0161, Martin" . "616912" . . . . "Psychiatrie" . "RIV/00216208:11150/03:00004314!RIV08-MSM-11150___" . "Multiple System Atrophy with Dementia"@en . . "Multisyst\u00E9mov\u00E1 Atrofie s demenc\u00ED"@cs . "RIV/00216208:11150/03:00004314" . . "Multiple; System; Atrophy; Dementia"@en . "Multisyst\u00E9mov\u00E1 Atrofie s demenc\u00ED" . . . . "136;137" . "Masopust, Ji\u0159\u00ED" . . . "Suppl. 2" . "Multisyst\u00E9mov\u00E1 Atrofie s demenc\u00ED"@cs . "Multisyst\u00E9mov\u00E1 Atrofie s demenc\u00ED" . "S" . "Urbanov\u00E1, Elen" . "CZ - \u010Cesk\u00E1 republika" . "Multisyst\u00E9mov\u00E1 atrofie (MSA) je sporadick\u00E1 neurodegenerativn\u00ED choroba neur\u010Dit\u00E9 etiologie a patogeneze. Klinicky se jedn\u00E1 o kombinace extrapyramid\u00E1ln\u00EDch, cerebel\u00E1rn\u00EDch, pyramid\u00E1ln\u00EDch a autonomn\u00EDch dysfunkc\u00ED. Diagn\u00F3za stanovuje podle krit\u00E9ri\u00ED mo\u017Enou, pravd\u011Bpodobnou a definitivn\u00ED MSA. N\u00E1\u0161 pacient je \u010Dty\u0159iat\u0159icetilet\u00FD mu\u017E, kter\u00FD trp\u00ED atypickou neurologickou symptomatologi\u00ED a kognitivn\u00ED poruchou neur\u010Dit\u00E9 etiologie.Tento p\u0159\u00EDpad ilustruje relevanci detailn\u00EDho neuropsychologick\u00E9ho hodnocen\u00ED a u\u017Eite\u010Dnost kvantitativn\u00EDho rozboru D2 receptoru pomoc\u00ED 123I-IBMZ SPECT u pacient\u016F s norm\u00E1ln\u00ED MRI a s podez\u0159en\u00EDm na MSA. P\u0159\u00EDtomnost demence se nepova\u017Euje za znak MSA. Kognitivn\u00ED porucha je v tomto p\u0159\u00EDpad\u011B jednou z inici\u00E1ln\u00EDch syndrom\u016F a \u0159ad\u00ED se k rozs\u00E1hl\u00E9 klinickopatologick\u00E9 komplexit\u011B MSA. Vzhledem k tomu, \u017Ee \u017E\u00E1dn\u00E1 l\u00E9\u010Debn\u00E1 terapie nen\u00ED zn\u00E1ma, l\u00E9\u010Dba je p\u0159edev\u0161\u00EDm podp\u016Frn\u00E1." .